Insulet Corporation $PODD Shares Sold by Beacon Investment Advisory Services Inc.

Beacon Investment Advisory Services Inc. lowered its holdings in Insulet Corporation (NASDAQ:PODD) by 11.5% during the fourth quarter, Holdings Channel.com reports. The firm owned 71,950 shares of the medical instruments supplier’s stock after selling 9,390 shares during the period. Beacon Investment Advisory Services Inc.’s holdings in Insulet were worth $20,451,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of PODD. True Wealth Design LLC boosted its stake in Insulet by 288.0% during the third quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 72 shares during the period. Whittier Trust Co. of Nevada Inc. raised its stake in shares of Insulet by 48.9% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 131 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 43 shares during the period. Measured Wealth Private Client Group LLC acquired a new position in shares of Insulet in the 3rd quarter worth approximately $49,000. Quent Capital LLC acquired a new position in shares of Insulet in the 3rd quarter worth approximately $49,000. Finally, Osterweis Capital Management Inc. purchased a new position in shares of Insulet during the 2nd quarter worth approximately $51,000.

Insiders Place Their Bets

In related news, Director Michael R. Minogue purchased 2,030 shares of the business’s stock in a transaction on Wednesday, February 25th. The shares were bought at an average price of $246.23 per share, for a total transaction of $499,846.90. Following the acquisition, the director directly owned 17,483 shares in the company, valued at $4,304,839.09. This trade represents a 13.14% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.39% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

PODD has been the topic of a number of research analyst reports. Weiss Ratings reissued a “hold (c)” rating on shares of Insulet in a research report on Thursday, January 22nd. Zacks Research lowered Insulet from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 5th. Truist Financial cut their price objective on Insulet from $390.00 to $360.00 and set a “buy” rating on the stock in a report on Thursday, February 19th. Stifel Nicolaus decreased their target price on Insulet from $370.00 to $350.00 and set a “buy” rating on the stock in a research note on Wednesday, February 4th. Finally, TD Cowen cut Insulet from a “buy” rating to a “hold” rating and set a $294.00 target price for the company. in a report on Monday, January 26th. Twenty research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $354.24.

Insulet Stock Performance

Shares of PODD stock opened at $208.22 on Monday. The firm has a 50 day moving average of $245.74 and a two-hundred day moving average of $288.32. The stock has a market capitalization of $14.66 billion, a PE ratio of 59.49, a P/E/G ratio of 1.25 and a beta of 1.42. The company has a quick ratio of 2.15, a current ratio of 2.81 and a debt-to-equity ratio of 0.61. Insulet Corporation has a 52 week low of $208.14 and a 52 week high of $354.88.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Wednesday, February 18th. The medical instruments supplier reported $1.55 earnings per share for the quarter, topping analysts’ consensus estimates of $1.48 by $0.07. The business had revenue of $783.80 million for the quarter, compared to analyst estimates of $768.31 million. Insulet had a return on equity of 24.90% and a net margin of 9.12%.The company’s revenue was up 31.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.15 earnings per share. On average, research analysts predict that Insulet Corporation will post 3.92 EPS for the current fiscal year.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.